ROM icon

ProShares Ultra Technology

45.02 USD
-0.62
1.36%
At close Apr 17, 4:00 PM EDT
1 day
-1.36%
5 days
-0.82%
1 month
-22.59%
3 months
-35.87%
6 months
-35.19%
Year to date
-35.00%
1 year
-18.09%
5 years
163.74%
10 years
841.84%
0
Funds holding %
of 7,407 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

225% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 4

70% more capital invested

Capital invested by funds: $26.2M [Q3] → $44.5M (+$18.3M) [Q4]

68% more call options, than puts

Call options by funds: $293K | Put options by funds: $174K

19% more funds holding

Funds holding: 47 [Q3] → 56 (+9) [Q4]

2.31% more ownership

Funds ownership: 3.63% [Q3] → 5.94% (+2.31%) [Q4]

27% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 11

Research analyst outlook

We haven’t received any recent analyst ratings for ROM.

Financial journalist opinion

Negative
Seeking Alpha
1 month ago
ROM: De-Risking Means De-Leveraging In Today's Environment
The market has shifted from consistent gains to increased volatility, signaling a potentially turbulent 2025, driven by factors like tariff news and economic uncertainty. Investors should proactively "de-risk" their portfolios by reducing leverage and high-beta investments, rather than reacting with "panic de-risking" during market downturns. The ProShares Ultra Technology ETF, a 2x leveraged technology fund, amplifies both gains and losses, making it particularly risky in a volatile market.
ROM: De-Risking Means De-Leveraging In Today's Environment
Neutral
Business Wire
4 months ago
Medincell and AIC Unveil New Positive Phase 3 Results for mdc-CWM: Major Subgroup Analysis Shows Reduced Pain and Opioid Use, and Accelerated Rehabilitation following Total Knee Replacement
MONTPELLIER, France--(BUSINESS WIRE)--Analysis of a major subgroup of patients undergoing a first Total Knee Replacement (TKR), representing over 70% of the trial population (108 out of 151), revealed the following benefits when comparing patients treated with F14/mdc-CWM (n=51) to those in the control group (n=57)1: 70% reduction in the number of opioid users at 3 months post-surgery, 28% reduction in the total quantity of opioids consumed during the first 3 months post-surgery, Lower daily kn.
Medincell and AIC Unveil New Positive Phase 3 Results for mdc-CWM: Major Subgroup Analysis Shows Reduced Pain and Opioid Use, and Accelerated Rehabilitation following Total Knee Replacement
Positive
Seeking Alpha
1 year ago
November Technology Dashboard, And The Risks Of ROM
Technology is the most overvalued sector, but the electronic equipment industry is undervalued relative to 11-year averages. 8 technology stocks were cheaper than their peers in November. ProShares Ultra Technology ETF: why the leveraged tech ROM ETF is risky.
Charts implemented using Lightweight Charts™